As the U.S. stock market concludes a strong year on a weak note, with major indices like the Dow experiencing significant monthly losses, investors are reflecting on opportunities within various sectors. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking potential growth despite their somewhat outdated label. By focusing on companies that exhibit solid financial health and promising prospects, investors can uncover potential value in this niche segment of the market.
|
Name |
Share Price |
Market Cap |
Financial Health Rating |
|
BAB (OTCPK:BABB) |
$0.77 |
$6.03M |
★★★★★★ |
|
Inter & Co (NasdaqGS:INTR) |
$4.22 |
$1.84B |
★★★★☆☆ |
|
QuantaSing Group (NasdaqGM:QSG) |
$3.08 |
$111.43M |
★★★★★★ |
|
Kiora Pharmaceuticals (NasdaqCM:KPRX) |
$3.30 |
$9.9M |
★★★★★★ |
|
ZTEST Electronics (OTCPK:ZTST.F) |
$0.29 |
$10.49M |
★★★★★★ |
|
CBAK Energy Technology (NasdaqCM:CBAT) |
$0.94 |
$97.13M |
★★★★★☆ |
|
Imperial Petroleum (NasdaqCM:IMPP) |
$3.01 |
$93.12M |
★★★★★★ |
|
Golden Growers Cooperative (OTCPK:GGRO.U) |
$4.50 |
$67.38M |
★★★★★★ |
|
BTCS (NasdaqCM:BTCS) |
$2.47 |
$43.38M |
★★★★★★ |
|
Smith Micro Software (NasdaqCM:SMSI) |
$1.31 |
$24.65M |
★★★★★☆ |
Click here to see the full list of 733 stocks from our US Penny Stocks screener.
Here’s a peek at a few of the choices from the screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing medicines for immune-mediated diseases, with a market cap of $298.94 million.
Operations: Aldeyra Therapeutics, Inc. does not currently report any revenue segments.
Market Cap: $298.94M
Aldeyra Therapeutics, Inc., a biotechnology company with a market cap of US$298.94 million, is pre-revenue and currently unprofitable but has made strides in reducing losses over the past five years. The company’s management and board are experienced, with an average tenure of 3.9 and 11.3 years respectively. Aldeyra’s short-term assets significantly exceed its liabilities, providing financial stability despite ongoing losses. Recent developments include the resubmission of a New Drug Application for reproxalap to the FDA after positive Phase 3 trial results for dry eye disease treatment, which could potentially impact future revenue streams if approved.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Adlai Nortye Ltd. is a clinical-stage biotechnology company dedicated to discovering and developing cancer therapies in the United States and Mainland China, with a market cap of $85.24 million.
